NDAORALTABLET
Approved
Aug 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LERITINE (anileridine hydrochloride) is an oral opioid analgesic approved in 1957 for pain management. It is a synthetic piperidine derivative with analgesic and antipyretic properties. The drug is administered orally in tablet form for moderate pain relief.
LOE Approaching
A product in late-stage lifecycle with limited commercial momentum; teams managing legacy products like this typically focus on cost management and portfolio optimization rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LERITINE offers limited growth potential but valuable experience in legacy product management, cost optimization, and regulatory compliance in a heavily scrutinized therapeutic area. Career advancement typically requires movement to growth-stage products within the broader portfolio.
Brand ManagerRegulatory Affairs Specialist
Worked on LERITINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.